Cara Therapeutics updates pipeline timelines; cash $123M, runway into 2H2024

Tvardi Therapeutics, Inc.

KORSUVA injection US launch ongoing; Japan approval expected 2H2023; EU launch 2H2022.
Oral difelikefalin Phase 3 for non-dialysis CKD-aP (KICK1/2) topline data 2H2024.
Phase 3 for atopic dermatitis (KIND1/2) internal readout 4Q2023, topline 1H2025.
Phase 2/3 for notalgia paresthetica (KOURAGE1) internal readout 2H2024.
Cash $123M as of Mar 31, 2023; no debt; cash runway into 2H2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.